Clinical Trial Update: A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety and immunogenicity of the GSK-580299 HPV vaccine in Chinese females has completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• GSK-580299 HPV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 1 | Status: COMPLETED | Results posted: 2009-12-17